Unique ID issued by UMIN | UMIN000053792 |
---|---|
Receipt number | R000061381 |
Scientific Title | Integrated analysis of the past mogamulizumab clinical trials for patients with ATL, PTCL and CTCL |
Date of disclosure of the study information | 2024/03/31 |
Last modified on | 2024/03/06 11:35:36 |
Integrated analysis of the past mogamulizumab clinical trials
Integrated analysis of the past mogamulizumab clinical trials
Integrated analysis of the past mogamulizumab clinical trials for patients with ATL, PTCL and CTCL
Integrated analysis of the past mogamulizumab clinical trials for patients with ATL, PTCL and CTCL
Japan | North America | South America |
Europe |
CCR4-positive Adult T-cell leukemia/lymphoma
CCR4-positive Peripheral T-cell lymphoma
Cutaneous T-cell lymphoma
Hematology and clinical oncology |
Malignancy
NO
Investigate an association of blood parameters and efficacy/safety of mogamulizumab treatments
Others
Comparing a change of blood parameters between responders and non-responders.
Blood parameter changes
Plasma concentration changes of mogamulizumab
Generalized models of blood parameters
Others,meta-analysis etc
Not applicable |
Not applicable |
Male and Female
Patients whose data was recorded participating the following clinical trials:
Phase 2 trial investigating mogamulizumab efficacy and safety for relapsed ATL patients
Phase 2 trial comparing mogamulizumab efficacy and safety with investigator's choice for relapsed/refractory ATL patients
Phase 2 clinical trial comparing efficacy and safety of mLSG15+mogamulizumab combination therapy with mLSG15 alone for untreated ATL patients
Phase 2 trial investigating mogamulizumab efficacy and safety for relapsed PTCL patients
Phase 2 trial investigating mogamulizumab efficacy and safety for relapsed/refractory PTCL patients
Phase 1/2 trial investigating mogamulizumab efficacy and safety for relapsed/refractory CTCL patients
Phase 3 trial comparing mogamulizumab efficacy and safety with vorinostat for relapsed/refractory CTCL patients
Patients participated the below trials but did not take mogamulizumab administration.
Phase 2 trial comparing mogamulizumab efficacy and safety with investigator's choice for relapsed/refractory ATL patients
Phase 3 trial comparing mogamulizumab efficacy and safety with vorinostat for relapsed/refractory CTCL patients
625
1st name | Yukihiro |
Middle name | |
Last name | Nishio |
Kyowa Kirin Co., Ltd.
Medical Affairs
100-0004
1-9-2, Otemachi, Chiyoda-ku, Tokyo
03-5205-7200
ma.oncology_2g.sd@kyowakirin.com
1st name | Yukihiro |
Middle name | |
Last name | Nishio |
Kyowa Kirin Co., Ltd.
Medical Affairs
100-0004
1-9-2, Otemachi, Chiyoda-ku, Tokyo
03-5205-7200
ma.oncology_2g.sd@kyowakirin.com
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Profit organization
Research Ethical Review Committee of Kyowa Kirin Co., Ltd
1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, JAPAN
03-5205-7200
researchethics.fj@kyowakirin.com
NO
2024 | Year | 03 | Month | 31 | Day |
Unpublished
Preinitiation
2024 | Year | 03 | Month | 05 | Day |
2024 | Year | 03 | Month | 05 | Day |
2024 | Year | 04 | Month | 01 | Day |
2026 | Year | 12 | Month | 31 | Day |
This study will use the data from clinical trials conducted by Kyowa Kirin Co., Ltd.
2024 | Year | 03 | Month | 06 | Day |
2024 | Year | 03 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061381
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |